Report: Renal cell carcinoma to be a $3.6bn market by 2023

A GlobalData report has revealed that the major markets of the US, the UK, France, Germany, Italy, Spain, Japan and China will lead the growth in renal cell carcinoma (RCC) from $2.1bn in 2013 to $3.6bn by 2023.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news